Leiden University Scholarly Publications

Your Search

Enabled Filters

  • (-) = Other
  • (-) = Medicine / Leiden University Medical Centre (LUMC)
  • (-) = Luijtens, K.

Refine Results

Resource Type

Availability

Creation Date

Faculty

Author

Show more

Language

Search results

  • RSS Feed
(1 - 6 of 6)
Efficacy Sustained After Dose De-escalation of Certolizumab Pegol in Rheumatoid Arthritis Patients: Post-hoc Analysis of the RAPID 2 Open-label Extension
Smolen, J.; Vollenhoven, R. van; Kavanaugh, A.; Luijtens, K.; Heijde, D. van der; Curtis, J. 2011
Efficacy Sustained After Dose De-escalation of Certolizumab Pegol in Rheumatoid Arthritis Patients: Post-hoc Analysis of the RAPID 2 Open-label Extension
Other
metadata only
Time to and Level of Initial DAS28 Change With Certolizumab Pegol Predicts the Likelihood of Having Low Disease Activity at Years 1 and 2 in Patients With Rheumatoid Arthritis
Haraoui, B.; Heijde, D. van der; Schiff, M.; Keystone, E.; Landewe, R.; Kvien, T.; ... ; Furst, D. 2011
Time to and Level of Initial DAS28 Change With Certolizumab Pegol Predicts the Likelihood of Having Low Disease Activity at Years 1 and 2 in Patients With Rheumatoid Arthritis
Other
metadata only
PROBABILITY OF ACHIEVING LOW DISEASE ACTIVITY AT 52 WEEKS IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH CERTOLIZUMAB PEGOL DEPENDS ON TIME TO AND LEVEL OF INITIAL RESPONSE
Heijde, D. van der; Schiff, M.; Keystone, E.; Landewe, R.; Kvien, T.; Curtis, J.; ... ; Furst, D. 2011
PROBABILITY OF ACHIEVING LOW DISEASE ACTIVITY AT 52 WEEKS IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH CERTOLIZUMAB PEGOL DEPENDS ON TIME TO AND LEVEL OF INITIAL RESPONSE
Other
metadata only
EFFICACY SUSTAINED AFTER DOSE DE-ESCALATION OF CERTOLIZUMAB PEGOL IN RHEUMATOID ARTHRITIS PATIENTS: POST-HOC ANALYSIS OF THE RAPID 2 OPEN-LABEL EXTENSION
Smolen, J.; Vollenhoven, R. van; Kavanaugh, A.; Luijtens, K.; Heijde, D. van der; Curtis, J. 2011
EFFICACY SUSTAINED AFTER DOSE DE-ESCALATION OF CERTOLIZUMAB PEGOL IN RHEUMATOID ARTHRITIS PATIENTS: POST-HOC ANALYSIS OF THE RAPID 2 OPEN-LABEL EXTENSION
Other
metadata only
Incremental Benefit of Open-Label Certolizumab Pegol plus MTX in Rheumatoid Arthritis (RA) Patients Following Double-Blind Placebo plus IVITX Treatment Out to 2 Years
Combe, B.; Schwartzman, S.; Massarotti, E.; Keystone, E.; Luijtens, K.; Heijde, D. van der 2010
Incremental Benefit of Open-Label Certolizumab Pegol plus MTX in Rheumatoid Arthritis (RA) Patients Following Double-Blind Placebo plus IVITX Treatment Out to 2 Years
Other
metadata only
INCREMENTAL BENEFIT OF OPEN-LABEL CERTOLIZUMAB PEGOL plus MTX IN RHEUMATOID ARTHRITIS (RA) PATIENTS FOLLOWING DOUBLE-BLIND PLACEBO plus MTX TREATMENT OUT TO 2 YEARS
Combe, B.; Schwartzman, S.; Massarotti, E.; Keystone, E.C.; Luijtens, K.; Heijde, D. van der 2010
INCREMENTAL BENEFIT OF OPEN-LABEL CERTOLIZUMAB PEGOL plus MTX IN RHEUMATOID ARTHRITIS (RA) PATIENTS FOLLOWING DOUBLE-BLIND PLACEBO plus MTX TREATMENT OUT TO 2 YEARS
Other
metadata only